ICMR transfers three indigenous biomedical technologies for advancements in cancer and infectious disease solutions
The Indian Council of Medical Research (ICMR) has licensed three indigenous biomedical technologies to pharmaceutical firms to advance cancer and infectious disease treatments. These include an anti-HPV therapeutic for cervical cancer and two next-generation bacterial infection vaccines.
Why it matters
Localizing the development of advanced medical technologies can significantly reduce costs and improve healthcare accessibility in India.
The Indian Council of Medical Research (ICMR), under its Medical Innovation Patent Mitra initiative, has granted licenses to three indigenous biomedical technologies to leading Indian pharmaceutical and vaccine manufacturers for further development, production and commercialisation.
These technologies include SHETA2, an innovative anti-HPV therapeutic candidate for the treatment of cervical intraepithelial neoplasia (CIN), which has been licensed to Emcure Pharmaceuticals.
In addition, two next generation vaccine technologies against enteric bacterial infections are included, which have been developed at ICMR-National Institute for Research on Bacterial Infections (ICMR-NIRBI), Kolkata. Their license has been given to Biological E.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in